Issue of Ordinary Shares
Updated : 17:35
Abzena plc
Issue of Ordinary Shares
Cambridge, UK, 29 March 2018 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that the Group has today issued 403,269 new ordinary shares of £0.002 each ('Ordinary Shares').
The Ordinary Shares were issued following the completion of the final vesting period of the restricted stock units issued to employees on the acquisition of The Chemical Research Solution LLC (known as 'TCRS') in December 2015 and the acquisition of PacificGMP in September 2015.
The new Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made for admission of the Ordinary Shares to trading on AIM, which is expected to occur at 8.00am on or around 6 April 2018.
Following Admission, the Company's enlarged issued share capital will comprise 214,220,399 ordinary shares of £0.002 each with voting rights. No shares are held in Treasury. The total number of voting rights in the Company is therefore 214,220,399. The figure of 214,220,399 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
-Ends-
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498
|
Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam
| +44 20 7260 1000 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners (PR advisors) Melanie Toyne Sewell / Alex Shaw
| +44 20 7457 2020 |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
· Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;
· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development;
· GMP manufacturer of ADC linkers, payloads & combined linker-payloads; and.
· GMP analytical services for biopharmaceutical manufacturing projects
For more information, please see www.abzena.com
This information is provided by RNS